Charles River To Merge With Leading Chinese Drug CRO WuXi PharmaTech If $1.6 Billion Transaction Is Approved By Beijing's Antitrust Czars

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.